Are you currently being treated for Relapsing Multiple Sclerosis?

TG Therapeutics

Study to Evaluate Efficacy when Transitioning from a Current Disease Modifying Therapy (DMT) to Ublituximab* (**ENHANCE** Trial)

What is this study about?

This 48-week study is to determine the efficacy and safety when switching from your current DMT to ublituximab and to determine if giving it over a shorter infusion time is safe and tolerable. If transitioning from another anti-CD20 therapy you may be eligible for a modified dosing schedule to eliminate the initial 150 mg dose of ublituximab.

*Ublituximab is approved by the US Food and Drug Administration (FDA) with the name BRIUMVI®, for adults with relapsing forms of multiple sclerosis. In this study, ublituximab is considered investigational because the initial dose of ublituximab may be different than the initial dose currently approved by the FDA, and some doses may be administered over shorter periods of time than the time currently approved by the FDA.

For more information on ENHANCE, and to see if you qualify, please see: https://clinicaltrials.gov/study/NCT05877963, ask your neurologist or health care provider, or scan QR code. You may also contact :

_____

You May Be Eligible To Participate In A Voluntary Research Study To Evaluate Efficacy When Transitioning From Your Current MS Therapy To Ublituximab

Are you eligible?

- Must be 18-65 years old
- Must not have been treated previously with ublituximab, alemtuzumab, cladribine, cyclophosphamide, mitoxantrone or daclizumab
- Must be neurologically stable for the past 30 days
- Must not have a history of severe or life-threatening Infusion Related Reaction on prior anti-CD20 therapy

Location

- ENHANCE is open in multiple locations across the United States
- Scan the QR code below to see Study Site locations

ENHANCE
Ublituximab in RMS

Protocol Amendment v4.0 22NOV2023